Webinar: HCV Treatment in 2016: Genotypes 1, 2, and 3
Facilitated by Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases
October 12, 2016
Other Trainings
Objectives
- List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
- Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
- Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.
Presentation
Slides
Facilitated by Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases
October 12, 2016
Objectives
- List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
- Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
- Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.
Presentation
Slides
Other Trainings
Facilitated by Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases
October 12, 2016
Objectives
- List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
- Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
- Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.
